CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

ITEM 5.03.

Effective December 8, 2016, the Board of Directors of Celgene
Corporation (the Company) amended and restated the Companys
by-laws (the Amended and Restated By-Laws) principally to
authorize holders of 25% or more of the Companys outstanding
shares to call special meetings of stockholders; permit
stockholders to include their nominees to the Board of Directors
in the Companys proxy materials under specified conditions; to
harmonize pre-existing by-law provisions with the foregoing
changes; and to effect certain other clarifying and updating
changes to the by-laws.

The foregoing description of the Amended and Restated By-Laws is
qualified in its entirety by reference to the full text thereof,
a copy of which is attached hereto as Exhibit 3.1 and
incorporated herein by reference.

d) Exhibits

Exhibit3.1 Amended and Restated By-Laws of the Company

About CELGENE CORPORATION (NASDAQ:CELG)

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

CELGENE CORPORATION (NASDAQ:CELG) Recent Trading Information

CELGENE CORPORATION (NASDAQ:CELG) closed its last trading session down -0.25 at 113.22 with 3,701,876 shares trading hands.